Copeland Capital Management’s Core Laboratories CLB Stock Holding History

Copeland Capital Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-58,400	Closed	-$6.57M	–	165
2016 Q1	$6.57M	Sell	58,400 -1,035	-2%	-$108K	0.45%	84
2015 Q4	$6.46M	Sell	59,435 -1,408	-2%	-$161K	0.37%	93
2015 Q3	$6.07M	Sell	60,843 -4,370	-7%	-$475K	0.37%	93
2015 Q2	$7.44M	Buy	65,213 +55,628	+580%	+$6.75M	0.38%	104
2015 Q1	$1M	Sell	9,585 -1,487	-13%	-$158K	0.07%	132
2014 Q4	$1.33M	Sell	11,072 -83,793	-88%	-$11M	0.1%	116
2014 Q3	$13.9M	Buy	94,865 +22,484	+31%	+$3.47M	1.41%	46
2014 Q2	$12.1M	Buy	72,381 +19,815	+38%	+$3.53M	1.35%	47
2014 Q1	$10.4M	Buy	+52,566	New	+$9.92M	1.27%	48

Other funds holding CLB

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Wedgewood Partners St Louis, Missouri $484M AUM 14.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

Copeland Capital Management's CLB Position: Q2 2016 in Review

Copeland Capital Management sold out of Core Laboratories (CLB) in Q2 2016, closing a stake of 58,400 shares — an estimated $6.57M sold.

Copeland Capital Management first reported a position in CLB in Q1 2014 and held it in 9 quarters. The position peaked at $13.9M in Q3 2014. 384 funds tracked by Wall St. Rank hold CLB as of Q2 2016.

Copeland Capital Management reported no remaining Core Laboratories position as of Q2 2016 after selling out during the quarter.
Copeland Capital Management sold 58,400 Core Laboratories shares in Q2 2016, an estimated $6.57M.
Copeland Capital Management first reported a position in Core Laboratories in Q1 2014 and held it in 9 quarters.
Copeland Capital Management's Core Laboratories position peaked at $13.9M in Q3 2014.
384 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2016.

Based on Copeland Capital Management's 13F filing for Q2 2016, filed 5 Aug 2016.